Cargando…

Onset of Graves' disease during long-term immunosuppressive therapy in a patient with membranous nephropathy

A 67-year-old man was referred to our department for thyrotoxicosis with intermittent palpitation and 4-kg weight loss during the previous month. At the first visit, the patient was treated with cyclosporine A (CyA) for membranous nephropathy during the last 3 years and 8 months. Laboratory studies...

Descripción completa

Detalles Bibliográficos
Autor principal: Iwasaki, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557087/
https://www.ncbi.nlm.nih.gov/pubmed/26336606
http://dx.doi.org/10.1530/EDM-15-0046
_version_ 1782388449399013376
author Iwasaki, Hiroaki
author_facet Iwasaki, Hiroaki
author_sort Iwasaki, Hiroaki
collection PubMed
description A 67-year-old man was referred to our department for thyrotoxicosis with intermittent palpitation and 4-kg weight loss during the previous month. At the first visit, the patient was treated with cyclosporine A (CyA) for membranous nephropathy during the last 3 years and 8 months. Laboratory studies revealed that the serum TSH level was <0.005 μU/ml, and free thyroxine (fT(4)) and triiodothyronine (fT(3)) levels were elevated at 2.76 ng/dl and 5.96 pg/ml respectively. Anti-TSH receptor antibody (TRAb) level was increased at 26.4%. A clinical diagnosis of Graves' hyperthyroidism was given, and then thyrostatic treatment with thiamazole (MMI) at a dose of 10 mg daily was initiated after CyA withdrawal. After the initiation of MMI therapy, serum fT(4) and fT(3) attained the normal level within 1.5 months, with relief of symptoms followed by a remarkable decrease in urinary protein excretion from 2.0–5.2 g/day to ≤0.03 g/day. The patient maintained euthyroid with a low titre of TRAb for the succeeding 2 years and then MMI was finally stopped. Neither a relapse of hyperthyroidism nor a flare-up of nephrotic syndrome was observed for 3 years after MMI discontinuation. CyA has conflicting effects on immunologic self-tolerance by modulation of self-reactive T cells and natural CD4(+)CD25(+)Foxp3(+) regulatory T cell (Treg) functions, and possibly becomes a triggering factor in the development of autoimmune disorders. This case may be interesting when considering the effect of each T cell subset on the development of Graves' disease. LEARNING POINTS: The balance between intrathyroidal self-reactive T cell and natural CD4(+)CD25(+)Foxp3(+) Treg functions determine self-tolerance in the thyroid. CyA not only halts the expansion of self-reactive T cells but also impairs the function of Treg, which can provoke an unwanted immune response. A change in thyroid autoimmunity during treatment with CyA may result in the development of autoimmune thyroid diseases (AITD). Renal involvement in AITD frequently manifests as nephrotic syndrome, and thyrostatic treatment with thiamazole may be effective for excessive proteinuria.
format Online
Article
Text
id pubmed-4557087
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-45570872015-09-02 Onset of Graves' disease during long-term immunosuppressive therapy in a patient with membranous nephropathy Iwasaki, Hiroaki Endocrinol Diabetes Metab Case Rep Unusual Effects of Medical Treatment A 67-year-old man was referred to our department for thyrotoxicosis with intermittent palpitation and 4-kg weight loss during the previous month. At the first visit, the patient was treated with cyclosporine A (CyA) for membranous nephropathy during the last 3 years and 8 months. Laboratory studies revealed that the serum TSH level was <0.005 μU/ml, and free thyroxine (fT(4)) and triiodothyronine (fT(3)) levels were elevated at 2.76 ng/dl and 5.96 pg/ml respectively. Anti-TSH receptor antibody (TRAb) level was increased at 26.4%. A clinical diagnosis of Graves' hyperthyroidism was given, and then thyrostatic treatment with thiamazole (MMI) at a dose of 10 mg daily was initiated after CyA withdrawal. After the initiation of MMI therapy, serum fT(4) and fT(3) attained the normal level within 1.5 months, with relief of symptoms followed by a remarkable decrease in urinary protein excretion from 2.0–5.2 g/day to ≤0.03 g/day. The patient maintained euthyroid with a low titre of TRAb for the succeeding 2 years and then MMI was finally stopped. Neither a relapse of hyperthyroidism nor a flare-up of nephrotic syndrome was observed for 3 years after MMI discontinuation. CyA has conflicting effects on immunologic self-tolerance by modulation of self-reactive T cells and natural CD4(+)CD25(+)Foxp3(+) regulatory T cell (Treg) functions, and possibly becomes a triggering factor in the development of autoimmune disorders. This case may be interesting when considering the effect of each T cell subset on the development of Graves' disease. LEARNING POINTS: The balance between intrathyroidal self-reactive T cell and natural CD4(+)CD25(+)Foxp3(+) Treg functions determine self-tolerance in the thyroid. CyA not only halts the expansion of self-reactive T cells but also impairs the function of Treg, which can provoke an unwanted immune response. A change in thyroid autoimmunity during treatment with CyA may result in the development of autoimmune thyroid diseases (AITD). Renal involvement in AITD frequently manifests as nephrotic syndrome, and thyrostatic treatment with thiamazole may be effective for excessive proteinuria. Bioscientifica Ltd 2015-08-05 2015 /pmc/articles/PMC4557087/ /pubmed/26336606 http://dx.doi.org/10.1530/EDM-15-0046 Text en © 2015 The authors This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en_GB) .
spellingShingle Unusual Effects of Medical Treatment
Iwasaki, Hiroaki
Onset of Graves' disease during long-term immunosuppressive therapy in a patient with membranous nephropathy
title Onset of Graves' disease during long-term immunosuppressive therapy in a patient with membranous nephropathy
title_full Onset of Graves' disease during long-term immunosuppressive therapy in a patient with membranous nephropathy
title_fullStr Onset of Graves' disease during long-term immunosuppressive therapy in a patient with membranous nephropathy
title_full_unstemmed Onset of Graves' disease during long-term immunosuppressive therapy in a patient with membranous nephropathy
title_short Onset of Graves' disease during long-term immunosuppressive therapy in a patient with membranous nephropathy
title_sort onset of graves' disease during long-term immunosuppressive therapy in a patient with membranous nephropathy
topic Unusual Effects of Medical Treatment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557087/
https://www.ncbi.nlm.nih.gov/pubmed/26336606
http://dx.doi.org/10.1530/EDM-15-0046
work_keys_str_mv AT iwasakihiroaki onsetofgravesdiseaseduringlongtermimmunosuppressivetherapyinapatientwithmembranousnephropathy